Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Perampanel on Neurophysiology Tests
NCT03653741Phase 4Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2018
- Primary completion
- Nov 2021
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of perampanel in epilepsy, sponsored by Weill Cornell Medicine. Primary endpoints: Change in Baseline Visual Evoked Potential (P100) Amplitude at 7 hours, Change in Baseline Visual Evoked Potential (P100) Latency at 7 hours and 5 more. Started Oct 2018; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03653741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03653741.